Physician
Oncology
Robert Jotte practices Oncology. He studied medicine at Vanderbilt University School of Medicine. He over the years received 1 awards: "Meaningful Use Stage 1 Certification". Robert Jotte is a published doctor as well. He has 17 publications published. The latest was: Myristylation of FBR v-fos dictates the differentiation pathways in malignant osteosarcoma. Robert M. Jotte accepts all Medicare patients.
Publications
- An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
- Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative.
- PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carbo...
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy.
- Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable n...
- Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-...
- Reovirus-induced alterations in gene expression related to cell cycle regulation.
- Reovirus-induced alteration in expression of apoptosis and DNA repair genes with potential roles in viral pathogenesis.
- Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
- Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-base...
- Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
- Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage II...
- TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells.
- Myristylation of FBR v-fos dictates the differentiation pathways in malignant osteosarcoma.
- Myristylation-dependent transactivation by FBR v-fos is regulated by C/EBP.
- Myristylation alters DNA-binding activity and transactivation of FBR (gag-fos) protein.
Schools
Vanderbilt University School Of Medicine
University Colo Health Science Center
University Of Colorado
Procedures Preformed
- Breast Cancer Treatment
- Cancer Counseling
- Cancer Treatment
- Genetic Counseling Services
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Colorado
-
Vanderbilt University School of Medicine
Hospital
-
Sky Ridge Medical Center
Drug Facts
| NPI NUMBER |
|
1669457032 |
| NPPES Provider LastName |
|
JOTTE |
| NPPES Provider FirstName |
|
ROBERT |
| NPPES Provider ZIPCode |
|
801245520 |
| NPPES Provider State |
|
CO |
| Specialty Description |
|
Medical Oncology |
| Total Claim Count |
|
1180.0 |
| Distinct Opioid Count |
|
7.0 |
| Opioid Claim Count |
|
125.0 |
| Percent Opioid Claims |
|
10.59 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1669457032 |
| Last Name Of The Provider |
JOTTE |
| First Name Of The Provider |
ROBERT |
| View All |
|
Doctor Directory | TOS | twitter | FB | Angel | blog
